A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

by | Jun 22, 2026 | Clinical Trials | 0 comments

​ Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: VS-7375

Sponsors: Verastem, Inc.

Not yet recruiting Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: VS-7375
Sponsors: Verastem, Inc.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *